Pathological factors evaluating prostate cancer

Histology and Histopathology

Volumn 22, Issue 10-12, 2007, Pages 1291-1300

  Yu, Yan Ping ^a   Luo, J H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AMACR; Androgen receptor; E cadherin; Gleason grading; Hepsin; NKX3.1; p27kip1

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANDROGEN RECEPTOR; ANTIANDROGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HEPSIN; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CASTRATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GLEASON SCORE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; METHYLATION; MICROARRAY ANALYSIS; NONHUMAN; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; REVIEW; ADENOCARCINOMA; BLOOD; GENETIC MARKER; GENETICS; MALE; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34748891795     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Asatiani E., Huang W.X., Wang A., Rodriguez Ortner E., Cavalli L.R., Haddad B.R. and Gelmann E.P. (2005). Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 65, 1164-1173.
2. Asian G., Irer B., Tuna B., Yorukoglu K., Saatcioglu F. and Celebi I. (2006). Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol. Res. Pract. 202, 93-98.
3. Ben-Izhak O., Lahav-Baratz S., Meretyk S., Ben-Eliezer S., Sabo E., Dirnfeld M., Cohen S. and Ciechanover A. (2003). Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J. Urol. 170, 241-245.
4. Bieberich C.J., Fujita K., He W.W. and Jay G. (1996). Prostate-specific and androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 271, 31779-31782.
5. Bostwick D.G. and Foster C.S. (1999). Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer. Semin. Urol. Oncol. 17, 222-272.
6. Brooks J.D., Weinstein M., Lin X., Sun Y., Pin S.S., Bova G.S., Epstein J.I., Isaacs W.B. and Nelson W.G. (1998). CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidem. Biomark. Prev. 7, 531-536.
7. Burd C.J., Petre C.E., Moghadam H., Wilson E.M. and Knudsen K.E. (2005). Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol. Endocrinol. 19, 607-620.
8. Carducci M.A., DeWeese T.L., Nelson W.G., Simons J.W., Sinibaldi V. and Eisenberger M.A. (1996). Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin. Oncol. 23, 56-62.
9. Celebi J.T., Shendrik I., Silvers D.N. and Peacocke M. (2000). Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 37, 653-657.
10. Cheng L., Sebo T.J., Slezak J., Pisansky T.M., Bergstralh E.J., Neumann R.M., Iczkowski K.A., Zincke H. and Bostwick D.G. (1998). Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer 83, 2164-2171.
11. Chesire D.R., Ewing C.M., Sauvageot J., Bova G.S. and Isaacs W.B. (2000). Detection and analysis at beta-catenin mutations in prostate cancer. Prostate 45, 323-334.
12. Chetcuti A., Margan S.H., Russell P., Mann S., Millar D.S., Clark S.J., Rogers J., Handelsman D.J. and Dong Q. (2001). Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res. 61, 6331-6334.
13. Cui J., Rohr L.R., Swanson G., Speights V.O., Maxwell T. and Brothman A.R. (2001). Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46, 249-256.
14. Dasari V.K., Deng D., Perinchery G., Yeh C.C. and Dahiya R. (2002). DNA methylation regulates the expression of Y chromosome specific genes in prostate cancer. J. Urol. 167, 335-338.
15. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A. and Chinnaiyan A.M. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
16. Di Cristofano A., Pesce B., Cordon-Cardo C. and Pandolfi P.P. (1998). Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355.
17. Dong J.T. (2001). Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 20, 173-193.
18. English H.F., Kyprianou N. and Isaacs J.T. (1989). Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15, 233-250.
19. Epstein J.I., Pizov G. and Walsh P.C. (1993). Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71, 3582-3593.
20. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C. and Partin A.W. (2005). Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J. Am. Med. Assoc. 294, 433-439.
21. Furuya Y. and Isaacs J.T. (1993). Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology 133, 2660-2666.
22. Gelmann E.P., Bowen C. and Bubendorf L. (2003). Expression of NKX3.1 in normal and malignant tissues. Prostate 55, 111-117.
23. Gleason D.F. (1966). Classification of prostatic carcinomas. Cancer Chemother. Rep. 50, 125-128.
24. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M. and Gerald W.L. (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913-923.
25. Graziano F., Humar B. and Guilford P. (2003). The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann. Oncol. 14, 1705-1713.
26. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., Delprado W., Stricker P.D., Grygiel J.J. and Sutherland R.L. (2001). Altered expression at androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 61, 423-427.
27. Isaacs W.B., Bova G.S., Morton R.A., Bussemakers M.J., Brooks J.D. and Ewing C.M. (1994). Molecular biology at prostate cancer. Semin. Oncol. 21, 514-521.
28. Jiang A.L., Zhang J.Y., Young C., Hu X.Y., Wang Y.M., Liu Z.F. and Hao M.L. (2004). Molecular cloning and characterization of human homeobox gene Nkx3.1 promoter. Acta Biochim. Biophys. Sin. (Shanghai) 36, 64-67.
29. Kibel A.S., Faith D.A., Bova G.S. and Isaacs W.B. (2000). Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J. Urol. 164, 192-196.
30. Kito H., Suzuki H., Ichikawa T., Sekita N., Kamiya N., Akakura K., Igarashi T., Nakayama T., Watanabe M., Harigaya K. and Ito H. (2001). Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 49, 110-115.
31. Klezovitch O., Chevillet J., Mirosevich J., Roberts R.L., Matusik R.J. and Vasioukhin V. (2004). Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185-195.
32. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N. and Ittmann M. (2001). Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11563-11568.
33. Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., Hsieh W.S., Isaacs W.B. and Nelson W.G. (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11733-11737.
34. Lei Q., Jiao J., Xin L., Chang C.J., Wang S., Gao J., Gleave M.E., Witte O.N., Liu X. and Wu H. (2006). NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9, 367-378.
35. Leytus S.P., Loeb K.R., Hagen F.S., Kurachi K. and Davie E.W. (1988). A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 27, 1067-1074.
36. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H. and Parsons R. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
37. Li L.C., Zhao H., Nakajima K., Oh B.R., Ribeiro Filho L.A., Carroll P. and Dahiya R. (2001). Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer. J. Urol. 166, 705-709.
38. Lin F., Yu Y.P., Woods J., Cieply K., Gooding B., Finkelstein P., Dhir R., Krill D., Becich M.J., Michalopoulos G., Finkelstein S. and Luo J.H. (2001a). Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am. J. Pathol. 159, 1603-1612.
39. Lin X., Tascilar M., Lee W.H., Vles W.J., Lee B.H., Veeraswamy R., Asgari K., Freije D., van Rees B., Gage W.R., Bova G.S., Isaacs W.B., Brooks J.D., DeWeese T.L., De Marzo A.M. and Nelson W.G. (2001b). GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159, 1815-1826.
40. Litvinov I.V., Vander Griend D.J., Antony L., Dalrymple S., De Marzo A.M., Drake C.G. and Isaacs J.T. (2006). Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc. Natl. Acad. Sci. USA 103, 15085-15090.
41. Lou W., Krill D., Dhir R., Becich M.J., Dong J.T., Frierson H.F. Jr, Isaacs W.B., Isaacs J.T. and Gao A.C. (1999). Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 59, 2329-2331.
42. Luo J., Duggan D.J., Chen Y., Sauvageot J., Ewing C.M., Bittner M.L., Trent J.M. and Isaacs W.B. (2001). Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61, 4683-4688.
43. Luo J., Zha S., Gage W.R., Dunn T.A., Hicks J.L., Bennett C.J., Ewing C.M., Platz E.A., Ferdinandusse S., Wanders R.J., Trent J.M., Isaacs W.B. and De Marzo A.M. (2002a). Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62, 2220-2226.
44. Luo J.H., Yu Y.P., Cieply K., Lin F., Deflavia P., Dhir R., Finkelstein S., Michalopoulos G. and Becich M. (2002b). Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35.
45. Martens M.B. and Keller J.H. (2006). Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies. Mod. Pathol. 19, 287-290.
46. Maruyama R., Toyooka S., Toyooka K.O., Virmani A.K., Zochbauer-Muller S., Farinas A.J., Minna J.D., McConnell J., Frenkel E.P. and Gazdar A.F. (2002). Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer. Res. 8, 514-519.
47. Millar D.S., Ow K.K., Paul C.L., Russell P.J., Molloy P.L. and Clark S.J. (1999). Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 18, 1313-1324.
48. Moran P., Li W., Fan B., Vij R., Eigenbrot C. and Kirchhofer D. (2006). Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem. 281, 30439-30446.
49. Nakayama T., Watanabe M., Yamanaka M., Hirokawa Y., Suzuki H., Ito H., Yatani R. and Shiraishi T. (2001). The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab. Invest. 81, 1049-1057.
50. Nassar A., Amin M.B., Sexton D.G. and Cohen C. (2005). Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer. Appl. Immunohistochem. Mol. Morphol. 13, 252-255.
51. Ornstein D.K., Oh J., Herschman J.D. and Andriole G.L. (1998). Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol. Clin. North. Am. 25, 591-601.
52. Park J.H., Walls J.E., Galvez J.J., Kim M., Abate-Shen C., Shen M.M. and Cardiff R.D. (2002). Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 161, 727-735.
53. Perl A.K., Wilgenbus P., Dahl U., Semb H. and Christofori G. (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392, 190-193.
54. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., Tchinda J., Tomlins S.A., Hofer M.D., Pienta K.G., Kuefer R., Vessella R., Sun X.W., Meyerson M., Lee C., Sellers W.R., Chinnaiyan A.M. and Rubin M.A. (2006). TMPRSS2:ERG Fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341.
55. Pillinger D.J. and Wilkinson R. (1971). Initiation of malignant transformation and the significance of changes in transfer RNA methylase enzymes. Cancer Res. 31, 630-632.
56. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M. and Koff A. (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22.
57. Prasad S.C., Thraves P.J., Soldatenkov V.A., Varghese S. and Dritschilo A. (1999). Differential expression of stathmin during neoplastic conversion of human prostate epithelial cells is reversed by hypomethylating agent, 5-azacytidine. Int. J. Oncol. 14, 529-534.
58. Quinn D.I., Henshall S.M. and Sutherland R.L. (2005). Molecular markers of prostate cancer outcome. Eur. J. Cancer 41, 858-887.
59. Ren B., Yu G., Tseng G.C., Cieply K., Gavel T., Nelson J., Michalopoulos G., Yu Y.P. and Luo J.H. (2006). MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25, 1090-1098.
60. Rennie P.S., Bruchovsky N. and Goldenberg S.L. (1988). Relationship of androgen receptors to the growth and regression of the prostate. Am. J. Clin. Oncol. 11 Suppl 2, S13-17.
61. Ribal M.J., Fernandez P.L., Lopez-Guillermo A., Farre X., Santos Y., Gibanel R., Cardesa A. and Alcaraz A. (2003). Low p27 expression predicts biochemical relapse after radical prostatectomy in patients with clinically localised prostate cancer. Anticancer Res. 23, 5101-5106.
62. Rubin M.A., Zhou M., Dhanasekaran S.M., Varambally S., Barrette T.R., Sanda M.G., Pienta K.J., Ghosh D. and Chinnaiyan A.M. (2002). alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. J. Am. Med. Assoc. 287, 1662-1670.
63. Santourlidis S., Florl A., Ackermann R., Wirtz H.C. and Schulz W.A. (1999). High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39, 166-174.
64. Santourlidis S., Warskulat U., Florl A.R., Maas S., Pulte T., Fischer J., Muller W. and Schulz W.A. (2001). Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma. Mol. Carcinog. 32, 36-43.
65. Schmitz W., Albers C., Fingerhut R. and Conzelmann E. (1995). Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur. J. Biochem. 231, 815-822.
66. Simmons S.O. and Horowitz J.M. (2006). Nkx3.1 binds and negatively regulates the transcriptional activity of Sp-family members in prostate-derived cells. Biochem. J. 393, 397-409.
67. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., Tamayo P., Renshaw A.A., D'Amico A.V., Richie J.P., Lander E.S., Loda M., Kantoff P.W., Golub T.R. and Sellers W.R. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209.
68. Sluyser M. (1994). Hormone resistance in cancer: the role of abnormal steroid receptors. Crit. Rev. Oncog. 5, 539-554.
69. Sreekumar A., Laxman B., Rhodes D.R., Bhagavathula S., Harwood J., Giacherio D., Ghosh D., Sanda M.G., Rubin M.A. and Chinnaiyan A.M. (2004). Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J. Natl. Cancer Inst. 96, 834-843.
70. Srikantan V., Valladares M., Rhim J.S., Moul J.W. and Srivastava S. (2002). HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res. 62, 6812-6816.
71. Stamey T.A., Warrington J.A., Caldwell M.C., Chen Z., Fan Z., Mahadevappa M., McNeal J.E., Nolley R. and Zhang Z. (2001). Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J. Urol. 166, 2171-2177.
72. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H. and Tavtigian S.V. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362.
73. Suzuki H., Sato N., Watabe Y., Masai M., Seino S. and Shimazaki J. (1993). Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 46, 759-765.
74. Swinnen J.V., Vanderhoydonc F., Elgamal A.A., Eelen M., Vercaeren I., Joniau S., Van Poppel H., Baert L., Goossens K., Heyns W. and Verhoeven G. (2000). Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int. J. Cancer 88, 176-179.
75. Tamada H., Kitazawa R., Gohji K. and Kitazawa S. (2001). Epigenetic regulation of human bone marphogenetic protein 6 gene expression in prostate cancer. J. Bone. Miner. Res. 16, 487-496.
76. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A. and Chinnaiyan A.M. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
77. Tsihlias J., Kapusta L.R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G.C., Klotz L.H. and Slingerland J.M. (1998). Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58, 542-548.
78. Tsuji A., Torres-Rosada A., Arai T., Le Beau M.M., Lemons R.S., Chou S.H. and Kurachi K. (1991). Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. J. Biol. Chem. 266, 16948-16953.
79. Usmani B.A., Shen R., Janeczko M., Papandreou C.N., Lee W.H., Nelson W.G., Nelson J.B. and Nanus D.M. (2000). Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin. Cancer Res. 6, 1664-1670.
80. Verkaik N.S., Trapman J., Romijn J.C., Van der Kwast T.H. and Van Steenbrugge G.J. (1999). Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int. J. Cancer 80, 439-443.
81. Verkaik N.S., van Steenbrugge G.J., van Weerden W.M., Bussemakers M.J. and van der Kwast T.H. (2000). Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest. 80, 1291-1298.
82. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J. and Kallioniemi O.P. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401-406.
83. Voelfer H.J., Augustus M., Madike V., Bova G.S., Carter K.C. and Gelmann E.P. (1997). Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57, 4455-4459.
84. Welsh J.B., Sapinoso L.M., Su A.I., Kern S.G., Wang-Rodriguez J., Moskaluk C.A., Frierson H.F. Jr and Hampton G.M. (2001). Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 5974-5978.
85. Woodson K., Hayes R., Wideroff L., Villaruz L. and Tangrea J. (2003). Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 55, 199-205.
86. Xu L.L., Srikantan V., Sesterhenn I.A., Augustus M., Dean R., Moul J.W., Carter K.C. and Srivastava S. (2000). Expression profile at an andragen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J. Urol. 163, 972-979.
87. Yang G., Ayala G., De Marzo A., Tian W., Frolov A., Wheeler T.M., Thompson T.C. and Harper J.W. (2002). Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 8, 3419-3426.
88. Yang R.M., Naitoh J., Murphy M., Wang H.J., Phillipson J., deKernion J.B., Loda M. and Reiter R.E. (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159, 941-945.
89. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M. and Luo J.H. (2004). Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790-2799.
90. Yu Y.P., Paranjpe S., Nelson J., Finkelstein S., Ren B., Kokkinakis D., Michalopoulos G. and Luo J.H. (2005). High throughput screening of methylation status of genes in prostate cancer using oligonucleotide methylation array. Carcinogenesis 26, 471-479.
91. Yu G., Tseng G.C., Yu Y.P., Gavel T., Nelson J., Wells A., Michalopoulos G., Kokkinakis D. and Luo J.H. (2006a). CSR1 suppresses tumor growth and metastasis of prostate cancer. Am. J. Pathol. 168, 597-607.
92. Yu Y.P., Tseng G.C. and Luo J.H. (2006b). Inactivation of myopodin expression associated with prostate cancer relapse. Urology 68, 578-582.
93. Zagars G.K., Ayala A.G., von Eschenbach A.C. and Pollack A. (1995). The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 31, 237-245.
94. Zagars G.K., Pollack A. and von Eschenbach A.C. (1997). Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79, 1370-1380.
95. Zha S., Ferdinandusse S., Denis S., Wanders R.J., Ewing C.M., Luo J., De Marzo A.M. and Isaacs W.B. (2003). Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 63, 7365-7376.